U.S. FDA Approves AOP Health’s RapiblykTM (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting

 VIENNA - Wednesday, 27. November 2024 AETOSWire 

(BUSINESS WIRE)--AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, announced that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for RapiblykTM (landiolol) in the hospital critical care setting for the treatment of the severe heart condition supraventricular tachycardia (atrial fibrillation and atrial flutter). The approval is based on clinical studies which demonstrated that RapiblykTM (landiolol) enables rapid management of the heart rate with minimal reduction of blood pressure. The approval will provide patients in the U.S. with a new treatment option and is an important step for AOP Health in bringing its mission to help patients and make an impact on rare diseases and critical care to the United States for the first time.

The approval was based on data of 5 randomized, double-blind, placebo-controlled studies. A total of 317 adults with supraventricular tachycardia were treated with landiolol: The heart rate decreased in 40-90% of treated patients within about 10 minutes, compared to 0-11% of patients who received placebo; heart rate decrease was defined as a >20% decrease in heart rate or a heart rate <100 bpm or at least intermittent cessation of the arrhythmia. In placebo-controlled clinical trials, adverse events were observed in 9,9% of landiolol treated patients vs. 1 % in patients treated with placebo.”

New Therapeutic option for rapid and “short-term” treatment of supraventricular tachycardia

AOP Health strives to offer solutions for patients with rare diseases or in critical care. Therefore, this approval marks an important moment for patients suffering from atrial fibrillation and atrial flutter in intensive care settings. “RapiblykTM approval in the US represents an important milestone for patients experiencing supraventricular tachycardia, including atrial fibrillation and atrial flutter, who need rapid and short-term heart rate reduction. After being available in Europe, we are delighted that this therapeutic option can be now available also for US patients” says Dr. Martin Steinhart, CEO of AOP Health.

Study Design

Five randomized, double-blind, placebo-controlled studies were conducted to test landiolol efficacy and safety in patients with supraventricular tachycardia (including atrial fibrillation and atrial flutter). A total of 317 adults were treated with landiolol: heart rate in patients treated with landiolol decreased of 40-90% vs 0-11% of patients who received placebo. Heart rate decrease was defined as a >20% decrease in heart rate or a heart rate <100 bpm or at least intermittent cessation of the arrhythmia. The infused dose of landiolol in these studies ranged from 9.3 to 74.6 mcg/kg/min. Adverse events were observed in 9,9% of landiolol treated patients (main adverse event was hypotension) vs. 1 % in patients treated with placebo.”

About supraventricular tachycardias

Supraventricular tachycardias (including atrial fibrillation and atrial flutter) can occur both in patients with and without heart disease. Because they can impair cardiac function, leading to acute cardiovascular problems, they require immediate medical attention.

About RapiblyckTM (landiolol) intravenous [280 mg of landiolol (equivalent to 300 mg of landiolol HCl) in a single-dose vial]

Landiolol is an ultra-short-acting adrenergic receptor antagonist, with beta 1/beta 2 selectivity ratio of 255. Landiolol is characterized by a fast onset of action and rapid reduction in heart rate without significantly lowering blood pressure. It is designed for use in emergency, cardiac critical care unit, operating room, and intensive care settings. It is used in emergency conditions and for short term treatments in critical care. It is therefore not intended for the treatment of chronic cardiac arrhythmias. It is registered in Europe for the treatment of supraventricular tachycardia, including atrial fibrillation or atrial flutter and for the management of non-compensatory sinus tachycardia.

INDICATION

RAPIBLYKTM is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

RAPIBLYKTM is contraindicated in patients with:

· Severe sinus bradycardia, sick sinus syndrome, heart block greater than first degree

· Decompensated heart failure

· Cardiogenic shock: May precipitate further cardiovascular collapse and cause cardiac arrest.

· Pulmonary hypertension: May precipitate cardiorespiratory decompensation.

· Hypersensitivity reactions, including anaphylaxis, to landiolol or any of the inactive ingredients

WARNINGS AND PRECAUTIONS

· Hypotension. Patients with hemodynamic compromise, hypovolemia, or on interacting medications are at increased risk of hypotension.

· Bradycardia. Patients with first-degree atrioventricular block, sinus node dysfunction, or conduction disorders are at increased risk of bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest.

· Cardiac Failure. Beta-blockers, like RAPIBLYKTM, can cause depression of myocardial contractility and may precipitate heart failure and cardiogenic shock.

· Reactive Airways Disease. Patients with reactive airways disease should, in general, not receive beta-blockers. Because of its relative beta-1 selectivity and titratability, RAPIBLYKTM injection may be titrated to the lowest possible effective dose. In the event of bronchospasm, stop the infusion immediately; a beta-2 stimulating agent may be administered with appropriate monitoring of ventricular rates.

· Use in Patients with Diabetes Mellitus and Hypoglycemia. Beta-blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at any time during treatment, especially in patients with diabetes mellitus, patients who are fasting (i.e., surgery, not eating regularly, or are vomiting), or children.

· Infusion Site Reactions. Infusion site reactions such as pain, swelling and erythema have occurred with the use of RAPIBLYKTM injection. Avoid infusions into small veins or through a butterfly catheter.

· Use in Patients with Prinzmetal’s Angina. Beta-blockers may exacerbate anginal attacks in patients with Prinzmetal’s angina because of unopposed alpha receptor–mediated coronary artery vasoconstriction.

· Use in Patients with Pheochromocytoma. If RAPIBLYKTM injection is used in the setting of pheochromocytoma, administer RAPIBLYK in combination with an alpha-blocker, and only after the alpha-blocker has been initiated. Administration of beta-blockers without opposing alpha blockade in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure from the attenuation of beta receptor-mediated vasodilation in skeletal muscle.

· Use in Patients with Peripheral Circulatory Disorders. RAPIBLYKTM injection may exacerbate peripheral circulatory disorders, such as Raynaud’s disease or syndrome, and peripheral occlusive vascular disease.

· Abrupt Discontinuation of RAPIBLYKTM Injection. Severe exacerbations of angina, myocardial infarction, and ventricular arrhythmias have been reported in patients with coronary artery disease upon abrupt discontinuation of beta-blocker therapy.

· Hyperkalemia. Beta-blockers, including RAPIBLYKTM injection, can cause increases in serum potassium and hyperkalemia. The risk is increased in patients with risk factors such as renal impairment. Intravenous administration of betablockers has been reported to cause potentially life-threatening hyperkalemia in hemodialysis patients. Monitor serum electrolytes during therapy with RAPIBLYKTM injection.

· Use in Patients with Metabolic Acidosis. Beta-blockers have been reported to cause hyperkalemic renal tubular acidosis. Acidosis in general may be associated with reduced cardiac contractility.

· Use in Patients with Hyperthyroidism. Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Abrupt withdrawal of beta blockade might precipitate thyroid storm; therefore, monitor patients for signs of thyrotoxicosis when withdrawing beta blocking therapy.

- Use in Patients at Risk of Severe Acute Hypersensitivity Reactions. When using beta-blockers, patients at risk of anaphylactic reactions may be more reactive to allergen exposure (accidental, diagnostic, or therapeutic). Patients using beta-blockers may be unresponsive to the usual doses of epinephrine used to treat anaphylactic or anaphylactoid reactions.

ADVERSE REACTIONS

The most important and common adverse reaction is hypotension, which in clinical trials occurred in 9.9% of patients receiving RAPIBLYKTM vs. 1% in those receiving placebo.

Please see the full Prescribing Information for RapiblykTM (landiolol), at https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217202s000lbl.pdf

About AOP Health

The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. The claim “Needs. Science. Trust.” sums up the foundation of the Group’s success: establishing trust through a continually high level of investment in research and development and a highly consistent and pragmatic orientation towards the needs of all stakeholders – especially the patients and their families as well as the healthcare professionals treating them.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241127506170/en/

Permalink

https://www.aetoswire.com/en/news/2711202443239

Contacts

Mag. Nina Roth

Director Corporate Communications

Nina.Roth@aop-health.com

+43-676-3131509

https://www.aop-health.com

From the US: 011-43-676-3131509

Commercial International Bank (CIB) and Truecaller Partner to Enhance Customer Experience in the Banking and Financial Sector.

 

• With Truecaller's Verified Business Customer Experience Solution suite, CIB provides its users with a trusted, verified, and contextual experience.

(BUSINESS WIRE) -- CIB, Egypt’s leading private-sector bank, has announced a strategic partnership with Truecaller, the premier global platform for verifying contacts and blocking unwanted communication. This partnership aims to elevate customer safety and streamline business communication within the banking industry, where trust is critical, using Truecaller’s Customer Experience Solution suite.

CIB offers a wide range of financial products and services to enterprises of all sizes, institutions, households, etc. With a strong presence in Egypt’s burgeoning Retail and SME Banking markets, CIB is committed to enhancing customers' trust and delivering a seamless banking experience. Trust and security play a pivotal role in safeguarding financial transactions and interactions.

Through this partnership, CIB will leverage Truecaller’s Customer Experience Solution to provide customers with a trusted, verified, and contextual communication experience. The Truecaller Customer Experience Solution empowers businesses to deliver trusted, personalized, and seamless communication by leveraging capabilities like Verified Business Caller ID, which ensures brand authenticity. Call Reason informs customers about the purpose of the call upfront.

The Verified Business Caller ID solution, part of the Customer Experience Suite, features the brand name, logo, category, verification tick, and a distinctive green badge. This combination ensures enhanced trustworthiness and instant customer recognition.

In an era of increasing unsolicited calls, CIB recognizes the necessity of offering a secure and timely communication experience. With Truecaller’s Customer Experience Solution, CIB can solidify its brand identity using the correct logo, verified tick, and on-time recognition, ensuring seamless communication between the bank and its customers.

By utilizing advanced communication capabilities such as Call Reason, CIB adds context to its calls, giving customers confidence before answering. This enhances communication efficiency while promoting transparency.

Commenting on the transaction, Mostafa Torky, Digital Media, Demand Generation & Marketing Insights Manager at CIB, said, “With the rising number of financial fraud cases, it is crucial for us at CIB to establish a secure communication environment with our customers. Truecaller’s Verified Business Caller ID solution has enabled us to foster a culture of trust and enhance customers’ experience.”

Priyam Bose, Global Head GTM & Developer Products at Truecaller, expressed excitement about the collaboration: “Truecaller is synonymous with trust and safety in communication. We are excited to partner with CIB to enable safer, smoother, and more seamless banking experiences while communicating with their customers. This partnership underscores our commitment to providing businesses in Egypt with solutions that foster trust, improve communication efficiency, and safeguard consumers.”

Truecaller’s Verified Business Customer Experience Solution empowers businesses to deliver personalized and secure communication by combining identity, context, feedback, and personalization in every call. This enhances brand presence while providing valuable insights through user feedback, significantly reducing phone-related frauds and scams. Over 2,500 active businesses globally have harnessed Truecaller’s solution to transform customer interactions across various industries, ensuring safer and more effective business communications.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241125632064/en/

Permalink
https://aetoswire.com/en/news/2611202443194

Contacts

press@truecaller.com

PUMA Signs Blockbuster Long-Term Partnership With the Portuguese Football Federation

HERZOGENAURACH, Germany - Wednesday, 27. November 2024

(BUSINESS WIRE)--Sports company PUMA has signed a long-term agreement with the Portuguese Football Federation (FPF), one of the world’s most popular national teams. Starting in 2025, PUMA will equip all male, female and youth teams as well as the federation’s futsal, beach football and E-Sports teams.

Portugal, the 2016 European Champions and 2018/19 Nations League Winners, are known for their captivating style of play, which has earned them many fans all over the world and the largest number of followers on social media of any national football federation worldwide.

“Signing a top-tier national team was one of our priorities in football and I am very excited to welcome a team as popular as Portugal to the PUMA Family,” said Arne Freundt, PUMA CEO. “Given the large number of fans all over the world and the great potential of the next generation of this squad, we are looking forward to the upcoming big tournaments such as the 2026 World Cup.”

For PUMA, the deal offers the opportunity to continue writing Portuguese football history. In the 1960s, PUMA became the partner of legendary player Eusébio, known as “O Rei” (“The King”), for whom it created the iconic PUMA KING football boot. Eusébio was the top scorer of the 1966 World Cup when he led his team to a third place in the tournament.

“We were attracted to PUMA because of the way in which they engage with the fans and tell the unique story of every team they work with” said Fernando Gomes, President of the FPF. “We look forward to creating an exciting range of products with them which will resonate with our large fan base all over the world.”

PUMA will unveil the new products and its creative direction for the partnership in early 2025.

PUMA

PUMA is one of the world’s leading Sports Brands, designing, developing, selling, and marketing footwear, apparel, and accessories. For more than 70 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs more than 16,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241127980673/en/

Permalink

https://www.aetoswire.com/en/news/2711202443240

Contacts

Luke Haidarovic – Lead Marketing Europe & Global PR & Media Teamsports – luke.haidarovic@puma.com

Robert-Jan Bartunek – Corporate Communications – robert.bartunek@puma.com

Abu Dhabi’s Technology Innovation Institute Inaugurates Open-Source AI Summit with Critical Discussions on the Future of AI

 

300+ international AI experts from tech giants including Meta and Google DeepMind exploring topics such as ethical considerations in AI ownership, innovations in sustainable AI computing, and compute power

Abu Dhabi, United Arab Emirates, 26 November 2024:

The Open-Source AI Summit Abu Dhabi, hosted by the Technology Innovative Institute (TII), a global applied science research center, has kicked off with critical conversations that will shape the global AI agenda. The summit, taking place at the St. Regis Saadiyat Island today and tomorrow with 300+ in attendance, converges with growing international focus on the pull and push between open- and closed-source AI.

“There are two critical choices when referring to AI,” said H.E. Faisal Al Bannai, the Secretary General of the Advanced Technology Research Council and Adviser to the UAE President. “You can leverage a closed-source AI model that belongs to a company. They control it, including the data you give it. Innovation begins and ends with them.

“Alternatively, you can leverage an open-source model that grows within the community. We innovate together, and anyone, anywhere, can access and build on it. If AI is going to be part of the fabric of our society—and it will—countries, companies, and individuals need to decide who controls it. Opening Falcon AI models was TII’s contribution to the world.’”

Dr. Najwa Aaraj, the Chief Executive Officer of TII, who opened the summit, said, “The Open-Source AI Summit Abu Dhabi is a defining moment for global AI discourse. Falcon, like other open-source models, unites scientists, developers, and innovators to accelerate technological advancements as a catalyst for global change. We look forward to seeing the impact it will continue to have, particularly as we continue our work with the Falcon Foundation.”

The summit agenda continued with discussions from renowned speakers. including Dr. Belgacem Haba, the Vice President of the Adeia Corporation in the U.S., who spoke about the challenges that AI has created in the semiconductor manufacturing industry.

Prof. Philip Torr, a Professor and Chief Scientific Advisor at Oxford University in the U.K, spoke about who should own AI, touching on potential drawbacks as well as regulation, and arguing that in the long-term, the benefits of open-source AI outweigh the risks.

Dr. Hakim Hacid, the Chief Researcher of TII’s AI Research Center, said, “We believe open-source AI is the way forward, but it is far from simple—there are challenges and questions about control, policy, compute power, and hardware that we need to address. That is why we’re convening so many global experts at this summit and will continue to do so in future years in partnership with the Falcon Foundation. These conversations are crucial.”

Later speakers will include Dr. Natalia Vassilieva, the Vice President and Field CTO of Cerebras Systems in the U.S., Dr. June Paik, the Founder and CEO of FuriosaAI in the U.S., Dr. Armand Joulin, a Research Director at Google DeepMind in France, and Dr. Michal Valko, the Principal Llama Engineer at Meta Paris in France. They will speak about degrees of AI openness, sustainable AI computing, creating more compact LLMs, leveraging foundation models for trustworthy algorithms, and more.

TII’s Dr. Jingwei Zuo will speak about Falcon Mamba, the first State Space Language Model, built using entirely new architecture and launched earlier this year.

The summit will culminate in a panel led by TII on their vision for open-source AI.

TII’s Falcon AI LLM series has garnered global recognition. The series began with the launch of Falcon 40B, the UAE’s first open-source LLM, in May 2023. Since then, subsequent Falcon models have consistently ranked among the top open-source AI models globally, as validated by the independent industry leaderboard, Hugging Face. A new model of Falcon is expected by the end of 2024.

*Source: AETOSWire

Contacts:

Victoria Meven

victoria.meven@edelman.com

 

Viromed Medical AG: Cold Plasma as a Digital Antibiotic for the Lungs

  PINNEBERG, Germany - Tuesday, 26. November 2024

Innovative prevention measure for ventilator-associated pneumonia reaches next stage

Use of cold plasma can prevent tens of thousands of deaths in Germany alone

Study led by expert from the renowned research network BREATH, Hortense Slevogt

 

(BUSINESS WIRE)--Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) is pushing forward research into cold plasma for the prevention of ventilator-associated pneumonia (VAP). Under the scientific direction of the outstanding expert Prof. Dr. Hortense Slevogt, BREATH scientist at the Hannover Medical School, the innovative project is investigating the safety and efficacy of cold plasma to kill bacteria in the respiratory tract for approval as a therapy.

The official announcement of the BREATH research network in this regard was published on November 22, 2024.

The renowned expert network BREATH (Biomedical Research in End-stage and Obstructive Lung Disease Hannover) is one of the five sites of the German Center for Lung Research (DZL) and uniquely unites internationally recognized expertise in translational respiratory medicine. The research network consists of the four strong partners Hannover Medical School, Leibniz Universität Hannover, Fraunhofer ITEM and CAPNETZ FOUNDATION.

VAP is a common and serious complication in mechanically ventilated patients, occurring in patients who are invasively ventilated for at least 48 hours. Studies show that VAP affects 23–36% of mechanically ventilated patients and is associated with prolonged ventilation, extended ICU and hospital stays, and an estimated mortality rate of 10–13%. In Germany alone, approximately 486,000 patients required mechanical ventilation in ICUs in 2023, highlighting the need for VAP prevention measures.

Uwe Perbandt, CEO of Viromed Medical AG, explained: “Even in the past, people often did not die from injuries but from the infections that followed. Today, we are heading towards a similar scenario. Due to the increasing resistance of germs, many people can no longer be helped. An infection is synonymous with death. Furthermore, antibiotics in the human body sometimes take days to reach the source of the disease. We do not have these problems with cold plasma. It can reach the site of infection within a few minutes and destroy pathogens – including those that are already resistant to antibiotics – just as quickly. The most important advantage is that cold plasma destroys germs physically. And there can be no resistance to that. So, if the efficacy and safety of cold plasma continue to be confirmed in the course of the study, which I firmly believe they will, we have here, in effect, a ‘digital antibiotic’ that will take us a big step forward in the fight against many diseases. This way, we can save tens or even hundreds of thousands of lives. In my opinion, this asset can increase the value of the AG significantly. Since BREATH published the news on Friday, we have already received numerous international inquiries.”

Prof. Dr. Hortense Slevogt, Clinic for Pneumology and Infectiology, MHH: “Ventilator-associated pneumonia not only has a high mortality rate but also places a significant burden on the healthcare system due to increased antibiotic use, longer patient stays, and higher treatment costs. The growing antibiotic resistance of pathogens makes new, non-antibiotic approaches urgently necessary. If the positive preliminary results of our study are confirmed, cold plasma could revolutionize the treatment of ventilated patients.”

About Viromed Medical AG:

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region, including DAX companies such as Volkswagen and Lufthansa, state and federal authorities and ministries as well as 1,100 hospitals, 7,000 pharmacies and 11,000 medical practices.

Cold atmospheric plasma (CAP) has been scientifically proven to inactivate harmful viruses, fungi and bacteria and has the potential to revolutionize conventional treatment methods in a wide variety of areas. Viromed Medical AG is doing important pioneering work in this field. The clearly superior CAP is already being used to treat difficult-to-heal wounds. Viromed is currently conducting clinical trials for use in pulmonary medicine. Viromed Medical AG is pursuing the goal of further advancing the use of CAP in medicine in the coming years and realizing the corresponding growth potential.

Language:		English
Company:		Viromed Medical AG
		Flensburger Straße 18
		25421 Pinneberg
		Germany
Phone:		+49 4101 809960
E-mail:		kontakt@viromed-medical.de
Internet:		https://www.viromed-medical-ag.de/
ISIN:		DE000A3MQR65
WKN:		A3MQR6
Listed:		Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt (Basic Board), Hamburg

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241126157435/en/

Permalink
https://www.aetoswire.com/en/news/2611202443189

Contacts

Viromed Medical AG
Uwe Perbandt
CEO
Email: kontakt@viromed-medical.de
www.viromed-medical-ag.de

 

Blackstone Credit & Insurance Announces $1 Billion Infrastructure Loan Portfolio Purchase From Santander

 NEW YORK

(BUSINESS WIRE)--Blackstone and Santander Corporate & Investment Banking today announced an agreement under which funds managed by Blackstone Credit & Insurance (“BXCI”) will acquire interests in a $1 billion portfolio of high-quality infrastructure loans from Santander. The portfolio comprises loans that finance assets located largely in Western Europe and the US across the digital infrastructure, utility scale renewable, energy efficiency and transportation sectors.

Robert Horn, Global Head of Infrastructure & Asset Based Credit at BXCI, said: “This transaction is consistent with our approach to working with leading financial institutions on large-scale, long-term, efficient solutions that support their capital goals.”

Marcel Patiño, Global Head of Private Debt Mobilization at Santander CIB, said: “We are delighted to partner with Blackstone on this strategic transaction as we look to streamline our balance sheet while supporting further growth by Santander as a leading advisor and arranger in the Structured Finance space.”

Jacob Nowack, Managing Director at BXCI, added: “We are excited to work with Santander to further scale our relationship as it aligns with Blackstone’s deep roots in the infrastructure credit market and BXCI’s focus on increasing its investment activities in Europe.”

BXCI’s Infrastructure and Asset Based Credit platform manages over $80 billion and has over 70 investment professionals, among the largest in the asset-backed marketplace. The platform is focused on providing investment grade credit, non-investment grade credit, and structured investments across the real economy in sectors such as digital infrastructure, energy transition infrastructure, consumer finance, commercial finance, and residential real estate.

Santander CIB is one of the leading banks globally in energy and infrastructure advisory and financings, offering tailored solutions to both corporate and institutional clients.

About Blackstone Credit & Insurance

Blackstone Credit & Insurance (“BXCI”) is one of the world’s leading credit investors. Our investments span the credit markets, including private investment grade, asset based lending, public investment grade and high yield, sustainable resources, infrastructure debt, collateralized loan obligations, direct lending and opportunistic credit. We seek to generate attractive risk-adjusted returns for institutional and individual investors by offering companies capital needed to strengthen and grow their businesses. BXCI is also a leading provider of investment management services for insurers, helping those companies better deliver for policyholders through our world-class capabilities in investment grade private credit.

About Santander

Banco Santander (SAN SM) is a leading commercial bank, founded in 1857 and headquartered in Spain and one of the largest banks in the world by market capitalization. The group’s activities are consolidated into five global businesses: Retail & Commercial Banking, Digital Consumer Bank, Corporate & Investment Banking (CIB), Wealth Management & Insurance and Payments (PagoNxt and Cards). This operating model allows the bank to better leverage its unique combination of global scale and local leadership. Santander aims to be the best open financial services platform providing services to individuals, SMEs, corporates, financial institutions and governments. The bank’s purpose is to help people and businesses prosper in a simple, personal and fair way. Santander is building a more responsible bank and has made a number of commitments to support this objective, including raising €220 billion in green financing between 2019 and 2030. At the end of the third quarter of 2024, Banco Santander had €1.3 trillion in total funds, 171 million customers, 8,100 branches and 208,000 employees.

Santander Corporate & Investment Banking (Santander CIB) is Santander’s global division that supports corporate and institutional clients, offering tailored services and value-added wholesale products suited to their complexity and sophistication, as well as to responsible banking standards that contribute to the progress of society.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241125396347/en/

Permalink

https://www.aetoswire.com/en/news/2611202443195

Contacts

Media

Blackstone

Felix Lettau

felix.lettau@blackstone.com

Santander

Santander Corporate Communications

comunicacion@gruposantander.com

Regnology Acquires VERMEG’s RegTech Division – AGILE – to Solidify Position as Global Market Leader

  Acquisition Creates the Largest Global Ecosystem Connecting Financial Regulators and the Regulated

(BUSINESS WIRE)--Regnology, a leading software provider with a focus on regulatory reporting solutions, announced today the acquisition of VERMEG's regulatory reporting division – AGILE – which was previously part of the Lombard Risk portfolio. This strategic move underscores Regnology’s commitment to advancing regulatory reporting and solidifies its position as a global leader in end-to-end regulatory reporting solutions for large banks and other financial institutions seeking comprehensive and innovative offering from a single, trusted provider.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241124525888/en/

Through this acquisition, VERMEG’s robust regulatory reporting solution will be integrated into the Regnology Platform. The AGILE solution suite currently supports over 150 global and international banks spanning the UK, Europe, Asia Pacific, and North America. By incorporating this suite into its offerings, Regnology will enhance its ability to deliver flexible, end-to-end reporting solutions, ranging from comprehensive data management to report generation and submission, all powered by advanced cloud technology. This aligns with the company's goal to support the transition to granular data and improve automation and data flow across organizations.

This acquisition also expands further Regnology’s international footprint and local expertise. Following the recent acquisition of CG3-1, the combined offering will support both broker-dealer and bank reporting for all types and sizes of regulated financial entities from Tier 1 banks and broker-deals to local community banks in North America. Similarly, the combined company has significant APAC coverage and customer base that includes banks in Hong Kong, Singapore, and Australia together with a number of major regulators across the region.

Rob Mackay, Regnology CEO, commented: “This consolidation marks a pivotal moment in our swift growth trajectory. Regnology will now have a truly global footprint in regulatory reporting to match our global leadership in supervisory collections. This gives us the ability to connect regulators and regulated financial institutions across the globe. We will continue to invest in our technology and our people and leverage our new locations to transform legacy reporting processes, at scale, into an efficient communication network.”

Badreddine Ouali, VERMEG Founder and Co-CEO, stated: “By joining forces with Regnology, AGILE will benefit from a broader global platform and enhanced opportunities for growth and innovation. This strategic move allows VERMEG to concentrate on our core strengths in Collateral Management and Insurance, ensuring we continue to deliver exceptional value to our clients. We are confident that this partnership will drive long-term success for both our companies and our dedicated teams.”

Lutz Kregel, Managing Director, Nordic Capital Advisors, added: “When investing four years ago, Nordic Capital saw great opportunities to support Regnology in transforming the regulatory reporting industry. Since then, the Regnology team has been working diligently, driven by a forward-looking and innovative vision, to ready industry stakeholders for the future of financial regulation, prioritizing efficiency and stability. Together, we’re now reaching a new milestone by looking to creating this global game-changer in regulatory reporting. Nordic Capital is excited about Regnology’s continued journey.”

About Regnology

Regnology is a leading global provider of innovative solutions for supervisory, regulatory and tax reporting. Over 35,000 financial institutions, 70 regulators and tax authorities rely on our solutions to streamline their processes, enhance data quality, and improve efficiency. Building on our unified data ingestion model, Regnology is uniquely positioned to support regulators in data collection and supervisory processes, and the regulated across the full regulatory reporting value chain. Leveraging the expertise of 900+ employees in 16 countries, we help clients navigate the complexities of an ever-evolving, data-intensive regulatory landscape.

For more information, visit www.regnology.net.

About VERMEG

Founded in 1993, VERMEG provides software solutions to over 500 blue-chip clients in more than 40 countries across the banking, insurance, and wealth management industries. The company’s high-quality platform offers best-in-class tools to automate processes and drive digitalization in financial services. Headquartered in Amsterdam with offices in 16 countries, VERMEG employs over 1,000 people worldwide. For more information, visit www.vermeg.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241124525888/en/

Permalink
https://aetoswire.com/en/news/2511202443157

Contacts

Mireille Adebiyi – Chief Marketing Officer
Email: mireille.adebiyi@regnology.net